Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02269059 | Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) | PHASE1 | COMPLETED | 13 | — | — | Dec 1, 2014 | Apr 1, 2015 | Jul 27, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| GT1 Participants | EXPERIMENTAL | Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel. |
| GT3 Participants | EXPERIMENTAL | Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel. |
| Name | Type | Description |
|---|---|---|
| MK-7680 | DRUG | MK-7680 10 mg and 100 mg capsules |
Inclusion Criteria: * Is in good health except for HCV infection * Is male or is a female of non-childbearing potential * Clinical diagnosis of HCV GT1 or GT3 with no evidence of mixed-GT or non-typeable infection Exclusion Criteria: * Has a history of clinically significant and not stably contro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |